Genmab A/S (GMAB) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Genmab A/S (GMAB) opera en el sector Healthcare, cotizado por última vez a $26.03 con una capitalización de mercado de 17B. La acción obtiene una puntuación de 58/100, una calificación moderada basada en 9 KPI cuantitativos.
Ultimo analisis: 15 mar 2026Genmab A/S (GMAB) Resumen de Asistencia Médica y Tuberías
Genmab A/S, a Danish biotechnology firm, focuses on developing innovative antibody therapeutics for cancer and other diseases, marketing key products like DARZALEX and teprotumumab. With a robust pipeline and strategic collaborations, Genmab aims to address unmet medical needs in oncology and immunology, holding a strong position in the antibody therapeutics market.
Tesis de Inversión
Genmab A/S presents a compelling investment case driven by its robust pipeline of antibody therapeutics and strategic partnerships. The company's marketed products, including DARZALEX and teprotumumab, generate substantial revenue, reflected in a profit margin of 16.7% and a gross margin of 93.6%. Key growth catalysts include the advancement of its Phase 2 clinical programs and potential regulatory approvals for novel therapies. The company's collaboration agreements with industry leaders like AbbVie and Janssen further de-risk its development pipeline. However, potential risks include clinical trial failures and increased competition in the biotechnology sector. With a market capitalization of $16.11 billion and a P/E ratio of 25.88, Genmab's valuation reflects its growth potential and established market presence.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market capitalization of $16.11 billion, indicating a strong market valuation.
- P/E ratio of 25.88, reflecting investor expectations for future earnings growth.
- Profit margin of 16.7%, demonstrating efficient operations and profitability.
- Gross margin of 93.6%, showcasing the high value of its therapeutic products.
- Beta of 0.75, suggesting lower volatility compared to the overall market.
Competidores y Pares
Fortalezas
- Strong portfolio of marketed products, including DARZALEX and teprotumumab.
- Robust pipeline of antibody therapeutics in clinical development.
- Strategic collaborations with leading pharmaceutical companies.
- High gross margin of 93.6%.
Debilidades
- Reliance on a limited number of key products for revenue generation.
- High research and development expenses.
- Potential for clinical trial failures.
- Exposure to regulatory risks.
Catalizadores
- Upcoming: Regulatory approval decisions for Teclistamab in relapsed/refractory multiple myeloma.
- Upcoming: Data readouts from Phase 2 clinical trials for Camidanlumab tesirine in Hodgkin lymphoma and solid tumors.
- Ongoing: Expansion of DARZALEX into new indications, including non-MM blood cancers and AL amyloidosis.
- Ongoing: Strategic collaborations with pharmaceutical companies to develop and commercialize new antibody therapeutics.
Riesgos
- Potential: Clinical trial failures for key pipeline candidates.
- Potential: Increased competition in the antibody therapeutics market.
- Potential: Patent expirations for key products.
- Ongoing: Regulatory risks associated with drug development and commercialization.
- Ongoing: Currency risk due to fluctuations in the exchange rate between the U.S. dollar and the Danish Krone.
Oportunidades de crecimiento
- Expansion of DARZALEX into New Indications: DARZALEX, Genmab's flagship product for multiple myeloma, has the potential for expansion into new indications, including non-MM blood cancers and AL amyloidosis. This expansion could significantly increase revenue streams and market share. The market for multiple myeloma therapeutics is projected to reach $37.5 billion by 2030, providing a substantial growth opportunity for Genmab.
- Advancement of Phase 2 Clinical Programs: Genmab has several promising products in Phase 2 clinical trials, including Teclistamab, Camidanlumab tesirine, and Mim8. Successful completion of these trials and subsequent regulatory approvals could lead to the launch of new blockbuster drugs. The timeline for these approvals is estimated to be within the next 3-5 years, offering a near-term growth catalyst.
- Strategic Collaborations and Partnerships: Genmab's collaboration agreements with industry leaders like AbbVie, Janssen, and BioNTech provide access to cutting-edge technologies and resources. These partnerships de-risk the development pipeline and accelerate the commercialization of new therapies. The value of these collaborations is estimated to be in the billions of dollars, offering a significant boost to Genmab's long-term growth prospects.
- Geographic Expansion into Emerging Markets: Genmab has the opportunity to expand its geographic presence into emerging markets, particularly in Asia and Latin America. These markets offer significant growth potential due to increasing healthcare spending and a growing prevalence of cancer and autoimmune diseases. The timeline for this expansion is estimated to be within the next 5-10 years.
- Development of Next-Generation Antibody Therapeutics: Genmab is actively engaged in the development of next-generation antibody therapeutics, including bispecific antibodies and antibody-drug conjugates. These innovative therapies have the potential to revolutionize the treatment of cancer and other diseases. The market for bispecific antibodies is projected to reach $12.4 billion by 2028, providing a substantial growth opportunity for Genmab.
Oportunidades
- Expansion into new therapeutic areas.
- Geographic expansion into emerging markets.
- Development of next-generation antibody therapeutics.
- Acquisition of complementary technologies or companies.
Amenazas
- Competition from other biotechnology and pharmaceutical companies.
- Patent expirations.
- Pricing pressures.
- Changes in healthcare regulations.
Ventajas competitivas
- Proprietary antibody technology platforms.
- Strong intellectual property protection.
- Established partnerships with leading pharmaceutical companies.
- Deep expertise in antibody therapeutics development.
Acerca de GMAB
Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab A/S is a biotechnology company dedicated to creating and developing differentiated antibody therapeutics for the treatment of cancer and other diseases. The company's evolution has been marked by strategic collaborations and a focus on innovative research and development. Genmab markets DARZALEX, a human monoclonal antibody for multiple myeloma (MM), teprotumumab for thyroid eye disease, ofatumurnab for chronic lymphocytic leukemia (CLL) and multiple sclerosis, and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its diverse product portfolio includes daratumumab for MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for hematological malignancies. Genmab also has approximately 20 active pre-clinical programs and several products in Phase 2 clinical trials, including Teclistamab, Camidanlumab tesirine, JNJ-64007957, JNJ-64407564, PRV-015, Mim8, and Lu AF82422. The company has established collaborations with CureVac AG, AbbVie, BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc., enhancing its research and development capabilities. Genmab's commitment to innovation and strategic partnerships positions it as a key player in the antibody therapeutics market.
Qué hacen
- Develops antibody therapeutics for cancer and other diseases.
- Markets DARZALEX for the treatment of multiple myeloma (MM).
- Markets teprotumumab for the treatment of thyroid eye disease.
- Develops ofatumurnab for chronic lymphocytic leukemia (CLL) and multiple sclerosis.
- Develops Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
- Conducts Phase 2 clinical trials for various therapeutic candidates.
- Engages in pre-clinical research and development programs.
Modelo de Negocio
- Develops and commercializes antibody therapeutics.
- Generates revenue through product sales and royalties.
- Collaborates with other pharmaceutical companies for research and development.
- Out-licenses its technologies and products to partners.
Contexto de la Industria
Genmab A/S operates within the biotechnology industry, a sector characterized by rapid innovation and intense competition. The market for antibody therapeutics is experiencing substantial growth, driven by the increasing prevalence of cancer and autoimmune diseases. Key competitors include companies like DGX, EXEL, ILMN, INCY, and ROIV, each vying for market share with their own unique therapeutic approaches. Genmab distinguishes itself through its focus on differentiated antibody therapeutics and strategic collaborations, positioning it to capitalize on the growing demand for innovative treatments.
Clientes Clave
- Patients with cancer and other diseases.
- Hospitals and clinics.
- Pharmaceutical companies.
- Healthcare providers.
Finanzas
Gráfico e información
Precio de la acción de Genmab A/S (GMAB): $26.03 (-0.08, -0.31%)
Últimas noticias
-
Genmab (GMAB) Fuels Confidence Based on Upcoming Epkinly and Petosemtamab Readouts
Yahoo! Finance: GMAB News · 26 mar 2026
-
Genmab And Lundbeck Amlenetug Data Adds Nuance To Valuation Debate
Yahoo! Finance: GMAB News · 20 mar 2026
-
Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees in Genmab
globenewswire.com · 19 mar 2026
-
Passing of Genmab A/S' Annual General Meeting
globenewswire.com · 19 mar 2026
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para GMAB.
Objetivos de Precios
Objetivo de consenso: $40.17
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de GMAB en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Competidores y Pares
Últimas Noticias
Genmab (GMAB) Fuels Confidence Based on Upcoming Epkinly and Petosemtamab Readouts
Genmab And Lundbeck Amlenetug Data Adds Nuance To Valuation Debate
Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees in Genmab
Passing of Genmab A/S' Annual General Meeting
Último análisis de Genmab A/S
Liderazgo: Jan van de Winkel
Chief Executive Officer
Jan van de Winkel has served as the Chief Executive Officer of Genmab A/S, managing a workforce of 2638 employees. His career spans over two decades in the biotechnology and pharmaceutical industries. He holds a Ph.D. in Immunology from the University of Nijmegen and has authored numerous scientific publications. Prior to joining Genmab, he held leadership positions at various biotech companies, focusing on antibody therapeutics and drug development. His expertise lies in translating scientific discoveries into innovative treatments for cancer and other diseases.
Historial: Under Jan van de Winkel's leadership, Genmab has achieved significant milestones, including the successful development and commercialization of DARZALEX and teprotumumab. He has overseen the expansion of Genmab's pipeline through strategic collaborations and acquisitions. His tenure has been marked by a focus on innovation and a commitment to developing differentiated antibody therapeutics. The company's market capitalization has grown substantially under his leadership, reflecting his strategic vision and execution.
Información de ADR de Genmab A/S Patrocinado
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. GMAB, as an ADR, allows U.S. investors to invest in Genmab A/S without the complexities of cross-border transactions. Each GMAB ADR represents a specific number of Genmab A/S shares traded on its home market, simplifying ownership and trading for U.S. investors.
- Ticker del mercado local: Nasdaq Copenhagen, Denmark
- Nivel de ADR: 2
- Ratio de ADR: 1:1
Lo Que los Inversores Preguntan Sobre Genmab A/S (GMAB)
¿Cuáles son los factores clave para evaluar GMAB?
Genmab A/S (GMAB) actualmente tiene una puntuación IA de 58/100, indicando puntuación moderada. La acción cotiza a un P/E de 25.4x, cerca del promedio del S&P 500 (~20-25x). Los analistas apuntan a $40.17 (+54% desde $26.03). Fortaleza clave: Strong portfolio of marketed products, including DARZALEX and teprotumumab.. Riesgo principal a monitorear: Potential: Clinical trial failures for key pipeline candidates.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de GMAB?
GMAB actualmente puntúa 58/100 (Grado C) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de GMAB?
Los precios de GMAB se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre GMAB?
Los analistas han establecido un precio objetivo de consenso de $40.17 para GMAB, representando un potencial alcista del 54% desde el precio actual de $26.03. La cobertura incluye calificaciones de compra, mantener y venta, estimaciones de ganancias y recientes mejoras o rebajas. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en GMAB?
Las categorías de riesgo para GMAB incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Clinical trial failures for key pipeline candidates.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de GMAB?
Genmab A/S (GMAB) tiene una relación P/E de 25.4, que está en un rango moderado. La relación P/E compara el precio de la acción con sus ganancias por acción. Compare con el promedio del S&P 500 (~20-25x) para contexto. Esto no es asesoramiento financiero.
¿Está GMAB sobrevalorada o infravalorada?
Determinar si Genmab A/S (GMAB) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Su relación P/E es 25.4. Objetivo de analistas $40.17 (+54% desde el precio actual). Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de GMAB?
Genmab A/S (GMAB) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on publicly available sources and may be subject to change.
- Financial data is as of 2026-03-15.